therapies for aggressive cancer and leukemia. An NF-kappa B
inhibitor named dehydroxymethylepoxyquinomicin
Yagudin, T.,
Zhao, Y.,
Gao, H.,
Zhang, Y.,
Yang, Y.,
Zhang, X.,
Ma, W.,
Daba, T.M.,
Ishmetov, V.,
Kang, K.,
Yang, B.,
Pan, Z. (2020)
infarction in order to facilitate the development of novel therapy.
Inhibitor of apoptosis
CAI, B.,
MA, W.,
WANG, X.,
SUKHAREVA, N.,
HUA, B.,
ZHANG, L.,
LI, X.,
LI, S.,
LIU, S.,
YU, M.,
XU, Y.,
SONG, R.,
XU, B.,
YANG, F.,
HAN, Z.,
DING, F.,
HUANG, Q.,
YU, Y.,
ZHAO, Y.,
WANG, J.,
BAMBA, D.,
PAN, Z.,
YANG, B.,
XU, J.,
ZAGIDULLIN, N.,
LI, F.,
TIAN, Y. (2020) ) phosphorylation and reduced its nuclear translocation by binding PP1A. Verteporfin, a YAP1
inhibitor decreased Lnc